Discovery of Thieno[2,3-d]pyrimidine-based KRAS G12D inhibitors as potential anticancer agents via combinatorial virtual screening

Discovery of Novel Quinazoline-based Covalent Inhibitors of KRAS G12C with Various Cysteine-targeting Warheads as Potential Anticancer Agents

(2021) Ling Li et al.   BIOORGANIC CHEMISTRY

Targeting RAS phosphorylation in cancer therapy: Mechanisms and modulators

(2021) Yuran Qiu et al.   Acta Pharmaceutica Sinica B

The Frequency of Ras Mutations in Cancer

(2020) Ian A. Prior et al.   CANCER RESEARCH

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer

(2020) Jay B. Fell et al.   JOURNAL OF MEDICINAL CHEMISTRY

Molecular epidemiology and diagnostics of KRAS mutations in human cancer

(2020) Jozsef Timar et al.   CANCER AND METASTASIS REVIEWS

Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway

(2020) Taryn E Gillies et al.   Molecular Systems Biology

GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf

(2020) Ziyang Zhang et al.   ACS Central Science

GTP Hydrolysis Without an Active Site Base: A Unifying Mechanism for Ras and Related GTPases

(2019) Ana R. Calixto et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Does Ras Activate Raf and PI3K Allosterically?

(2019) Ruth Nussinov et al.   Frontiers in Oncology

Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors

(2019) Brian A. Lanman et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

(2018) Matthew R. Janes et al.   CELL

Putting the brakes on KRAS-G12C nucleotide cycling

(2016) Lydia Shipman   NATURE REVIEWS DRUG DISCOVERY

Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma

(2014) John C Castle et al.   BMC GENOMICS

Drugging the undruggable RAS: Mission Possible?

(2014) Adrienne D. Cox et al.   NATURE REVIEWS DRUG DISCOVERY

Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation

(2009) Jacob P. Laubach et al.   EXPERIMENTAL HEMATOLOGY